Evidence-performance gap in primary care revisited in patients with diabetes

Experimental and Clinical Cardiology

Volumn 20, Issue 1, 2014, Pages

  Djalal, Sima ^a   Mikulicic, Fran ^a   Woitzek, Katja ^a   Chmiel, Corinne ^a   Senn, Oliver ^a   Rosemann, Thomas ^a   Vecellio, Marco ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Cardiovascular risk; Diabetes; Evidence performance gap; Guidelines; Primary care

Indexed keywords

ACETYLSALICYLIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN; METFORMIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; EVIDENCE BASED MEDICINE; FEMALE; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION SYSTEM; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; SWITZERLAND; SYSTOLIC BLOOD PRESSURE;

EID: 84898879710     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28:88-136. (Pubitemid 46137814)
2. Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013; 34:3035-3087.
3. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32:1769-1818.
4. Jiwa M, Meng X, Sriram D, Hughes J, Colagiuri S, Twigg SM, et al. The management of Type 2 diabetes: a survey of Australian general practitioners. Diabetes Res Clin Pract 2012; 95:326-332.
5. Seidu S, Khunti K. Non-adherence to diabetes guidelines in primary care - the enemy of evidence-based practice. Diabetes Res Clin Pract 2012; 95:301-302.
6. McCrate F, Godwin M, Murphy L. Attainment of Canadian Diabetes Association recommended targets in patients with type 2 diabetes: a study of primary care practices in St John's, Nfld. Can Fam Physician 2010; 56:e13-19.
7. Boyd CM, Vollenweider D, Puhan MA. Informing evidence-based decision-making for patients with comorbidity: availability of necessary information in clinical trials for chronic diseases. PLoS One 2012; 7:e41601.
8. Turner R. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853. (Pubitemid 28416718)
9. Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007; 99:21i-
10. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine 2008; 358:2560-2572. (Pubitemid 351831357)
11. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. New England Journal of Medicine 2009; 360:129-139.
12. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study. Lancet 1999; 353:617-622. (Pubitemid 29087981)
13. Riddle MC. Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation 2010; 122:844-846.
14. Turner R, Holman R, Stratton I, Cull C, Frighi V, Manley S, et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. British Medical Journal 1998; 317:703-713. (Pubitemid 28414300)
15. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the hypertension optimal treatment (HOT) randomised trial. Revista Portuguesa de Cardiologia 1998; 17:843-844. (Pubitemid 28536451)
16. Cushman WC, Evans GW, Byington RP, Goff Jr DC, Grimm Jr RH, Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. New England Journal of Medicine 2010; 362:1575-1585.
17. Howard BV, Roman MJ, Devereux RB, Fleg JL, Galloway JM, Henderson JA, et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: The SANDS randomized trial. JAMA - Journal of the American Medical Association 2008; 299:1678-1689. (Pubitemid 351519865)
18. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney International 2002; 61:1086-1097. (Pubitemid 34175478)
19. Collins R, Armitage J, Parish S, Sleight P, Peto R. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebocontrolled trial. Lancet 2002; 360:7-22. (Pubitemid 34756487)
20. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of Intensive Compared with Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis: A Randomized Controlled Trial. Journal of the American Medical Association 2004; 291:1071-1080 (Pubitemid 38541684)
21. Deedwania P, Stone PH, Merz CNB, Cosin- Aguilar J, Koylan N, Luo D, et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: Results of the Study Assessing Goals in the Elderly (SAGE). Circulation 2007; 115:700-707. (Pubitemid 46294760)
22. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. New England Journal of Medicine 2004; 350:1495-1504. (Pubitemid 38477774)
23. Wenger NK, Lewis SJ, Herrington DM, Bittner V, Welty FK. Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Annals of Internal Medicine 2007; 147:1-9. (Pubitemid 351664628)
24. Pedersen TR, Faergeman O, Kastelein JJP, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial. Journal of the American Medical Association 2005; 294:2437-2445. (Pubitemid 41627921)
25. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials. The Lancet 2010; 376:1670-1681.
26. Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013.
27. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55:1577-1596.
28. Burgmann K, Fatio SA, Jordi B, Rutishauser J. Medical care of type 2 diabetes mellitus in light of international and national recommendations: a retrospective analysis. Swiss Med Wkly 2013; 143:w13871.
29. Gerber PA, Spirk D, Brandle M, Thoenes M, Lehmann R, Keller U. Regional differences of glycaemic control in patients with type 2 diabetes mellitus in Switzerland: a national cross-sectional survey. Swiss Med Wkly 2011; 141:w13218.